Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus curvatus HY7601 + Lactobacillus plantarum KY1032
- Development stage
- Unknown
- Lead developer
- Hy Co
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus curvatus HY7601 + Lactobacillus plantarum KY1032 is a combination of two probiotic bacterial strains developed as a multi-strain probiotic supplement. This combination has been clinically studied for its effects on obesity and metabolic health. The mechanism of action involves modulation of the gut microbiota, leading to reduced body weight, visceral fat mass, waist circumference, and improved adiponectin levels in overweight individuals. The probiotics also increase beneficial gut bacteria such as Bifidobacteriaceae and Akkermansiaceae while decreasing potentially harmful families like Prevotellaceae and Selenomonadaceae[1][7]. Preclinical studies show that this combination reduces triglycerides by upregulating hepatic genes involved in lipid metabolism (ApoA-V, PPARα, FXR), inhibits adipogenesis, reduces cholesterol in plasma and liver, improves energy metabolism markers in the liver and adipose tissue, and suppresses diet-induced obesity[3][4][5][7]. These strains were originally isolated from Korean traditional fermented cabbage.
- Brand names
- hyLabs FatSlim
- Other names
- Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032L. curvatus HY7601 + L. plantarum KY1032
Beyond the preview
Go deeper on Lactobacillus curvatus HY7601 + Lactobacillus plantarum KY1032.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus curvatus HY7601 + Lactobacillus plantarum KY1032.